PATISIRAN
patisiran 10 mg/5 mL injection, 5 mL vial
PATISIRAN (14264R)
14264R
Body System:
Manner of administration:Injection
Restriction
Indication: Hereditary transthyretin amyloidosis
Treatment phase: Initial treatment
Restriction
Indication: Hereditary transthyretin amyloidosis
Treatment phase: Continuing treatment
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 3 | Max qty units: 3 | # of repeats: 7 | DPMQ: $37,349.79 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Onpattro | |||||